[Effect of alpha-lipoic acid and mexidol on neuro- and the affective status in patients at early stages of diabetic foot syndrome].
The study was designed to investigate effect of alpha-lipoic acid (alphaLA) and mexidol on clinical manifestations of diabetic neuropathy (DN) and the associated changes of the affective status in patients with diabetes mellitus at early stages of diabetic foot syndrome (DFS). Integral indicator of clinical symptoms of distal symmetric sensorimotor polyneuropathy (according to the neuropathic signs and symptoms scale) significantly decreased within 14 days after the onset of the treatment with alphaLA (600 mg/day) and mexidol (300 mg/day). Antineuropathic effect of alphaLA was associated with a rise in the left ventricular ejection fraction. Mexidol reduced the severity of DN-related depression and was more efficacious than alphaLA in terms of beneficial effect on spasms and paresthesia (pricking and burning sensation, numbness) in distal segments of the lower extremities. The above clinical effects of alphaLA and mexidol were unrelated to changes of glycemia, lipidemia amd lipid peroxidation.
Volchegorskiĭ
I A
IA
Alekseev
M N
MN
Volchegorskaia
M I
MI
Rassokhina
L M
LM
D000975:Antioxidants / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D017719:Diabetic Foot / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016743:Mental Competency; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index; D008063:Thioctic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome
D000975:Antioxidants; D010847:Picolines; C070020:emoxypine succinate; D008063:Thioctic Acid